JP2011527704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011527704A5 JP2011527704A5 JP2011517646A JP2011517646A JP2011527704A5 JP 2011527704 A5 JP2011527704 A5 JP 2011527704A5 JP 2011517646 A JP2011517646 A JP 2011517646A JP 2011517646 A JP2011517646 A JP 2011517646A JP 2011527704 A5 JP2011527704 A5 JP 2011527704A5
- Authority
- JP
- Japan
- Prior art keywords
- independent
- groups
- weight
- alkyl
- transcutol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 7
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 7
- -1 1,3-benzothiazolyl Chemical group 0.000 claims 6
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 4
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 3
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims 1
- 229920001817 Agar Polymers 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 241000978776 Senegalia senegal Species 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- 235000010489 acacia gum Nutrition 0.000 claims 1
- 239000008272 agar Substances 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000005956 isoquinolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical group [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001806 thionaphthenyl group Chemical group 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/171,515 | 2008-07-11 | ||
| US12/171,515 US8026271B2 (en) | 2008-07-11 | 2008-07-11 | Formulations of indol-3-yl-2-oxoacetamide compounds |
| PCT/US2009/050210 WO2010006234A2 (en) | 2008-07-11 | 2009-07-10 | Anticancer oral formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011527704A JP2011527704A (ja) | 2011-11-04 |
| JP2011527704A5 true JP2011527704A5 (https=) | 2012-08-16 |
| JP5596680B2 JP5596680B2 (ja) | 2014-09-24 |
Family
ID=41505721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517646A Expired - Fee Related JP5596680B2 (ja) | 2008-07-11 | 2009-07-10 | 経口抗がん製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8026271B2 (https=) |
| EP (1) | EP2310363B1 (https=) |
| JP (1) | JP5596680B2 (https=) |
| KR (1) | KR101627382B1 (https=) |
| CN (1) | CN102159541B (https=) |
| ES (1) | ES2426599T3 (https=) |
| TW (1) | TWI384984B (https=) |
| WO (1) | WO2010006234A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8026271B2 (en) * | 2008-07-11 | 2011-09-27 | National Health Research Institutes | Formulations of indol-3-yl-2-oxoacetamide compounds |
| CN104945420A (zh) | 2009-06-29 | 2015-09-30 | 因塞特公司 | 作为pi3k抑制剂的嘧啶酮类 |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| US8680108B2 (en) * | 2009-12-18 | 2014-03-25 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
| AR081823A1 (es) | 2010-04-14 | 2012-10-24 | Incyte Corp | DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| EP2655374B1 (en) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| DK2707101T3 (da) * | 2011-05-12 | 2019-05-13 | Proteostasis Therapeutics Inc | Proteostaseregulatorer |
| KR102507287B1 (ko) | 2011-09-02 | 2023-03-07 | 인사이트 홀딩스 코포레이션 | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| SI3831833T1 (sl) | 2015-02-27 | 2023-03-31 | Incyte Holdings Corporation | Postopki za pripravo inhibitorja PI3K |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| CA3101323A1 (en) | 2018-06-01 | 2019-12-05 | Incyte Corporation | Dosing regimen for the treatment of pi3k related disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6979456B1 (en) * | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
| US6372251B2 (en) * | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
| US20040092428A1 (en) * | 2001-11-27 | 2004-05-13 | Hongming Chen | Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof |
| US6903104B2 (en) * | 2001-12-06 | 2005-06-07 | National Health Research Institutes | Indol-3-YL-2-oxoacetamide compounds and methods of use thereof |
| MX2007006183A (es) * | 2004-11-24 | 2007-09-11 | Merck & Co Inc | Formulaciones farmaceuticas liquidas y semisolidas para administracion oral de una amida sustituida. |
| US20060134204A1 (en) * | 2004-12-21 | 2006-06-22 | Wong Patrick S | Complexes made using low solubility drugs |
| TWI376239B (en) * | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
| AU2007325628A1 (en) * | 2006-11-28 | 2008-06-05 | Marinus Pharmaceuticals | Nanoparticulate formulations and methods for the making and use thereof |
| AU2008206294A1 (en) * | 2007-01-16 | 2008-07-24 | Bipar Sciences, Inc. | Formulations for cancer treatment |
| US8026271B2 (en) * | 2008-07-11 | 2011-09-27 | National Health Research Institutes | Formulations of indol-3-yl-2-oxoacetamide compounds |
-
2008
- 2008-07-11 US US12/171,515 patent/US8026271B2/en not_active Expired - Fee Related
-
2009
- 2009-07-09 TW TW098123197A patent/TWI384984B/zh not_active IP Right Cessation
- 2009-07-10 EP EP09795224.6A patent/EP2310363B1/en not_active Not-in-force
- 2009-07-10 CN CN200980126979.4A patent/CN102159541B/zh not_active Expired - Fee Related
- 2009-07-10 ES ES09795224T patent/ES2426599T3/es active Active
- 2009-07-10 WO PCT/US2009/050210 patent/WO2010006234A2/en not_active Ceased
- 2009-07-10 JP JP2011517646A patent/JP5596680B2/ja not_active Expired - Fee Related
- 2009-07-10 KR KR1020117003208A patent/KR101627382B1/ko not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011527704A5 (https=) | ||
| RU2485942C2 (ru) | Бупропиона гидробромид и его терапевтические применения | |
| CN101410098B (zh) | 包括含亲脂性药物的纳米胶囊的微球 | |
| CN103260741B (zh) | 本体肠溶胶囊壳 | |
| JP2010523553A5 (https=) | ||
| JP2018058870A (ja) | 放出制御ポリマーの水性分散液並びにそのシェル及びカプセル | |
| JP2012502037A5 (https=) | ||
| Yang et al. | Curcumin-loaded gelatin nanoparticles cross the blood-brain barrier to treat ischemic stroke by attenuating oxidative stress and neuroinflammation | |
| CN100500137C (zh) | 用于片剂和囊片的膜包衣 | |
| JP2005514386A5 (https=) | ||
| JP2011225600A5 (https=) | ||
| JP2010501632A (ja) | 高安定性を示すソフトカプセルにおけるアセチルサリチル酸又はその誘導体の製剤 | |
| JP2020534246A (ja) | 重水素化ドンペリドン組成物、方法、及び調製 | |
| JP2019526537A5 (https=) | ||
| JP2014534196A5 (https=) | ||
| JP2007537258A5 (https=) | ||
| CA2633924A1 (en) | Gastric reflux resistant dosage forms | |
| JP2011088926A5 (https=) | ||
| RU2014149010A (ru) | Форма многослойного покрытия фармацевтической композиции для перорального применения, содержащей омега-3 жирную кислоту или ее алкиловый сложный эфир, а также лекарственное средство на основе статина | |
| JP2007526238A5 (https=) | ||
| JP2009544665A5 (https=) | ||
| CN1759829A (zh) | 一种度洛西汀肠溶微丸胶囊及其制备方法 | |
| JP2011046708A5 (https=) | ||
| ES2541141T3 (es) | Composición farmacéutica para el tratamiento de las enfermedades del hígado graso | |
| JP2007505105A5 (https=) |